Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ghent University

www.rug.ac.be

Latest From Medtronic PLC

OUS Approvals: Neurostim And Cardiovascular Lead June Surge

Approvals of neurostimulation and cardiology devices dominated the list of non-US medtech approvals in June. According to Medtech Insight's Approvals Tracker, there were 36 medtech approvals outside the US last total that month, including 28 CE marks in Europe, plus approvals from China, Canada, Australia/New Zealand and Brazil.

Approvals Innovation

US Approvals Analysis: FDA Delivers Strong Half-Year Volumes

US FDA Device-approval volumes were strong during the first half of 2017 for all review pathways. Medtronic and Siemens have so far captured the most 510(k) clearances, with Cook close behind. That and more from Medtech Insight's Approvals Tracker.

Approvals Innovation

Medtronic Computer Crash To Have Limited Impact

Despite a major a computer crash, Medtronic is confident it will meet its revenue growth projections for the first quarter. The company also says there is currently no indication the crash was the result of an outside agent such as the recent WannaCry and Petya worms.

Manufacturing Sales & Earnings

Admedus CEO Ready To Transform Company Again With TAVR

The ups, downs – and nearly outs – of ASX-listed health technologies manufacturer and distributor Admedus have made compelling reading in the past two years, but CEO Wayne Paterson has brought a competitive edge to a company that was lacking focus. Now he is looking to raise the bar again, aiming to use the company's proprietary Adapt patch technology in the TAVR space, while also pressing on with strategic plans for the therapeutic vaccines portfolio and adding scale.

Business Strategies Cardiovascular
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register